The European Union has granted CE Mark of approval to Embrella Cardiovascular’s aortic embolic protection device Embolic Deflector, to be marketed throughout Europe.

According to Wayne, Pa.-based Embrella, the protection device acts as a protective shield against debris and calcifications that may embolize the brain during transcathter aortic valve implantation procedures.

The device has been previously approved in Europe for use in high-risk patients with severe aortic stenosis.